PEN logo

Penumbra, Inc. Stock Price

NYSE:PEN Community·US$12.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

PEN Share Price Performance

US$318.10
78.78 (32.92%)
US$363.36
Fair Value
US$318.10
78.78 (32.92%)
12.5% undervalued intrinsic discount
US$363.36
Fair Value
Price US$318.10
AnalystConsensusTarget US$363.36
AnalystLowTarget US$238.98
AnalystHighTarget US$374.00

PEN Community Narratives

·
Fair Value US$363.36 12.5% undervalued intrinsic discount

STORM-PE Trial And New Therapies Will Expand Global Reach

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
·
Fair Value US$238.98 33.1% overvalued intrinsic discount

Hospital Protocol Shifts And Reimbursement Pressures Will Undermine Long-Term Vascular Procedure Momentum

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$374 14.9% undervalued intrinsic discount

Pulmonary Embolism Thrombectomy Adoption Will Drive Strong Long Term Value Creation

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$363.36
12.5% undervalued intrinsic discount
Revenue
12.75% p.a.
Profit Margin
14.96%
Future PE
57.89x
Price in 2029
US$447.28
US$238.98
33.1% overvalued intrinsic discount
Revenue
13.19% p.a.
Profit Margin
12.65%
Future PE
50.26x
Price in 2028
US$298.71

Trending Discussion

Updated Narratives

PEN logo

PEN: Stroke Device Approvals And Merger Outlook Will Drive Future Upside

Fair Value: US$374 14.9% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PEN logo

PEN: Pulmonary Embolism Trial And Merger Approval Will Support Stronger Outlook

Fair Value: US$363.36 12.5% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PEN logo

Hospital Protocol Shifts And Reimbursement Pressures Will Undermine Long-Term Vascular Procedure Momentum

Fair Value: US$238.98 33.1% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
2 Rewards

Penumbra, Inc. Key Details

US$1.5b

Revenue

US$474.3m

Cost of Revenue

US$980.0m

Gross Profit

US$808.9m

Other Expenses

US$171.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
4.35
67.38%
11.76%
0%
View Full Analysis

About PEN

Founded
2004
Employees
4700
CEO
Adam Elsesser
WebsiteView website
www.penumbrainc.com

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Recent PEN News & Updates

Narrative Update Jul 01

PEN: Stroke Device Approvals And Merger Outlook Will Drive Future Upside

Analysts have adjusted their price target for Penumbra to $374 from $355, citing updated assumptions related to discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Penumbra Penumbra received U.S. FDA clearance and European CE Mark approval for its THUNDERBOLT computer assisted vacuum thrombectomy system for acute ischemic stroke, the first CAVT platform approved in the U.S. specifically for stroke care, according to recent news reports.
Analysis Article Jun 19

Penumbra (PEN) Stock Could Be 12.7% Undervalued On STORM PE Trial Hopes

Penumbra (PEN) is back in focus after recent trading left the stock around $317.20, prompting investors to reassess its performance over the past month and past 3 months. See our latest analysis for Penumbra. Looking beyond the latest move, Penumbra’s 1 year total shareholder return of 23.42% contrasts with a year to date share price return of 2.51%, while the 3 year total shareholder return has declined 6.7%. This suggests that momentum has cooled after stronger recent gains. If you are...
Narrative Update Jun 17

PEN: Pulmonary Embolism Trial And Merger Approval Will Support Stronger Outlook

Analysts have maintained their Penumbra price target at approximately $363, noting only minor adjustments to factors such as the discount rate, assumptions about long-term revenue growth and profit margins, and the projected future P/E multiple. What’s in the News for Penumbra Boston Scientific announced plans to acquire Penumbra, with Artisan Partners highlighting the deal as confirmation of its prior investment thesis in Penumbra stock and using the transaction to exit its position.

Recent updates

No updates